Literature DB >> 3606944

Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.

G Milano, M C Etienne, M Frenay, R Khater, J L Formento, N Renee, J L Moll, M Francoual, M Berto, M Namer.   

Abstract

Recent biochemical and pharmacological findings concerning tamoxifen (TMX) have proven that both the unchanged drug and the main metabolites, N-desmethyltamoxifen (NDT) and 4-hydroxytamoxifen (4OHT) are biologically active. An HPLC method based on on-line post-column UV irradiation with fluorescence detection is described. Optimized conditions allowed complete and rapid separation of TMX 4OHT, NDT and two other recently reported metabolites, Y and Z. This method was applied to plasma and cytosol drug and metabolite analyses. In plasma, from the moment of initial drug administration until the steady state (after 1 month or more of continuous oral TMX treatment), the values of NDT to TMX ratios were completely reversed: 22 to 215 in mean %, P less than 0.01. The presence of metabolites Y and Z is significant. 4OHT, hardly detectable at the first dose, was measured at the steady state with high interpatient variability. It is hypothesized that metabolite evolution with time may be due to auto-induction of drug metabolism. In cytosols, which were all obtained during continuous TMX treatment, the ratios between TMX and metabolites were comparable to those observed in plasma, but with greater interpatient variability. Metabolite Y was not detectable in cytosols. This variability was not linked to the levels of cytosolic oestradiol receptors before initiation of treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606944      PMCID: PMC2001713          DOI: 10.1038/bjc.1987.103

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.

Authors:  M A Miller; M E Lippman; B S Katzenellenbogen
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

2.  Paired-ion chromatographic analysis of tamoxifen and two major metabolites in plasma.

Authors:  Y Golander; L A Sternson
Journal:  J Chromatogr       Date:  1980-01-11

3.  The binding of tamoxifen to human mammary carcinoma cytosol.

Authors:  R L Sutherland; L C Murphy
Journal:  Eur J Cancer       Date:  1980-09       Impact factor: 9.162

4.  Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer.

Authors:  P Wilkinson; G Ribeiro; H Adam; J Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Antiestrogen binding sites in human breast cancer biopsies. Measurement ligand-specificity and affinity, and correlation to estrogen and progesterone receptors.

Authors:  M Fernö; A Borg
Journal:  Anticancer Res       Date:  1985 May-Jun       Impact factor: 2.480

6.  Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.

Authors:  R R Reddel; L C Murphy; R E Hall; R L Sutherland
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

7.  Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare.

Authors:  R R Reddel; R L Sutherland
Journal:  Eur J Cancer Clin Oncol       Date:  1984-11

8.  Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer.

Authors:  C Fabian; L Tilzer; L Sternson
Journal:  Biopharm Drug Dispos       Date:  1981 Oct-Dec       Impact factor: 1.627

9.  Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules.

Authors:  C Fabian; L Sternson; M Barnett
Journal:  Cancer Treat Rep       Date:  1980 Jun-Jul

10.  Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers.

Authors:  H K Adam; J S Patterson; J V Kemp
Journal:  Cancer Treat Rep       Date:  1980 Jun-Jul
View more
  7 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

3.  Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes.

Authors:  Jun Chen; Steven C Halls; Joshua F Alfaro; Zhaohui Zhou; Ming Hu
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

Review 4.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

5.  Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells.

Authors:  M D Johnson; B R Westley; F E May
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

6.  Tamoxifen metabolism: pharmacokinetic and in vitro study.

Authors:  M C Etienne; G Milano; J L Fischel; M Frenay; E François; J L Formento; J Gioanni; M Namer
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

7.  Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells.

Authors:  Rin Nagaoka; Toshiharu Iwasaki; Nana Rokutanda; Akira Takeshita; Yukio Koibuchi; Jun Horiguchi; Noriaki Shimokawa; Yuichi Iino; Yasuo Morishita; Noriyuki Koibuchi
Journal:  Endocrine       Date:  2006-12       Impact factor: 3.925

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.